Heartflow (NASDAQ:HTFL) Price Target Raised to $40.00

Heartflow (NASDAQ:HTFL) had its price target boosted by equities researchers at Canaccord Genuity Group from $39.00 to $40.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective suggests a potential upside of 29.45% from the company’s current price.

A number of other research firms have also recently commented on HTFL. Morgan Stanley started coverage on Heartflow in a research note on Tuesday, September 2nd. They set an “equal weight” rating and a $35.00 target price on the stock. Wall Street Zen raised shares of Heartflow to a “hold” rating in a research note on Saturday, August 16th. Piper Sandler initiated coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They issued an “overweight” rating and a $38.00 price objective for the company. Stifel Nicolaus increased their price objective on Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Weiss Ratings started coverage on shares of Heartflow in a research note on Saturday, November 1st. They issued a “sell (d+)” rating for the company. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $38.60.

Heartflow Trading Down 13.5%

Shares of HTFL stock traded down $4.84 during trading hours on Thursday, hitting $30.90. The stock had a trading volume of 1,712,080 shares, compared to its average volume of 419,272. The business has a 50-day simple moving average of $34.73. Heartflow has a one year low of $26.56 and a one year high of $41.22.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings data on Friday, September 19th. The company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($1.26). The business had revenue of $43.42 million during the quarter, compared to the consensus estimate of $43.20 million.

Institutional Trading of Heartflow

Several hedge funds have recently made changes to their positions in the company. TFC Financial Management Inc. purchased a new stake in shares of Heartflow during the 3rd quarter worth approximately $40,000. Emerald Mutual Fund Advisers Trust acquired a new stake in shares of Heartflow during the 3rd quarter valued at approximately $4,418,000. TrueMark Investments LLC purchased a new stake in Heartflow during the third quarter worth $918,000. Baillie Gifford & Co. acquired a new position in shares of Heartflow during the 3rd quarter worth approximately $101,182,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Heartflow in the 3rd quarter valued at about $234,000.

Heartflow Company Profile

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.